The subgroup analyses of these major clinical trials indicate that certain ICI combination therapies may have some degree of effectiveness in treating NSCLC with STK11 or KEAP1 mutations, although their therapeutic benefits are generally limited (Figures 2A–D). The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.